Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-19
    E.g., 2018-10-19

Archive Search

4 results
12:00 AM, Mar 05, 2012  |  BC Week In Review | Company News  |  Sales & Marketing

ViroPharma sales and marketing update

ViroPharma launched Cinryze in the U.K. for the treatment and pre-procedure prevention of acute attacks of …
recombinant human hyaluronidase ( rHuPH20 ) drug delivery technology to develop a subcutaneous formulation of Cinryze
12:00 AM, Oct 31, 2011  |  BC Week In Review | Company News  |  Sales & Marketing

ViroPharma sales and marketing update

ViroPharma reported in its 3Q11 earnings that it launched hereditary angioedema (HAE) drug Cinryze in Germany …
12:00 AM, Nov 17, 2008  |  BC Week In Review | Company News  |  Sales & Marketing

ViroPharma sales and marketing update

ViroPharma plans to launch its Cinryze complement 1 (C1) esterase inhibitor in the first week of …
planned 20 sales reps. The wholesale acquisition price is $3,900 per dose. The label for Cinryze
recommends dosing every 3-4 days. The company also launched the CinryzeSolutions patient access program to help …
12:00 AM, Jun 09, 2008  |  BC Week In Review | Company News  |  Sales & Marketing

Lev, CuraScript Inc., CVS Caremark Corp., FFF Enterprises Inc. sales and marketing update

Lev signed exclusive multi-year agreements with CuraScript, CVS and FFF to distribute Cinryze (formerly C1-INH …
May, FDA accepted Lev's complete response to a January approvable letter. The PDUFA date for Cinryze